{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:02:09Z","timestamp":1770436929184,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.idc.2011.07.005","type":"journal-article","created":{"date-parts":[[2011,11,6]],"date-time":"2011-11-06T06:15:21Z","timestamp":1320560121000},"page":"773-788","source":"Crossref","is-referenced-by-count":32,"title":["Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases"],"prefix":"10.1016","volume":"25","author":[{"given":"Jennifer L.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasia","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.idc.2011.07.005_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In\u00a0vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2013a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus Med"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2011.07.005_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins\u2013understanding properties and mechanisms","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"19","key":"10.1016\/j.idc.2011.07.005_bib4","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2146\/ajhp070582","article-title":"Unlabeled uses of intravenous immune globulin","volume":"65","author":"Leong","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2011.07.005_bib5","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1537-2995.2006.00792.x","article-title":"Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature","volume":"46","author":"Darabi","year":"2006","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkl173","article-title":"Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation","volume":"58","author":"Sriskandan","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1526-0968.2001.005002115.x","article-title":"Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins","volume":"5","author":"Werdan","year":"2001","journal-title":"Ther Apher"},{"issue":"12","key":"10.1016\/j.idc.2011.07.005_bib9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1097\/01.CCM.0000295263.12774.97","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","article-title":"Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis","volume":"146","author":"Turgeon","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.idc.2011.07.005_bib11","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1097\/01.CCM.0000295312.13466.1C","article-title":"Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis","volume":"35","author":"Laupland","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.idc.2011.07.005_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001090","article-title":"Intravenous immunoglobulin for treating sepsis and septic shock","volume":"1","author":"Alejandria","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.idc.2011.07.005_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.shk.0000157302.69125.f8","article-title":"Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery","volume":"23","author":"Rodriguez","year":"2005","journal-title":"Shock"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/026765910101600205","article-title":"Treatment of sepsis in cardiac surgery: role of immunoglobulins","volume":"16","author":"Sablotzki","year":"2001","journal-title":"Perfusion"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1378\/chest.105.1.76","article-title":"Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients","volume":"105","author":"Pilz","year":"1994","journal-title":"Chest"},{"issue":"24","key":"10.1016\/j.idc.2011.07.005_bib16","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1001\/jama.267.24.3315","article-title":"Intravenous immunoglobulin therapy for toxic shock syndrome","volume":"267","author":"Barry","year":"1992","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.idc.2011.07.005_bib17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2013a comparative observational study. The Canadian Streptococcal Study Group","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1086\/514585","article-title":"Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome","volume":"26","author":"Stevens","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2011.07.005_bib20","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/606048","article-title":"Intravenous immunoglobulin in children with streptococcal toxic shock syndrome","volume":"49","author":"Shah","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/381979","article-title":"Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome","volume":"38","author":"Darenberg","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2011.07.005_bib22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/383045","article-title":"Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001","volume":"189","author":"Archibald","year":"2004","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004836-200405000-00005","article-title":"Factors associated with failure of metronidazole in Clostridium difficile-associated disease","volume":"38","author":"Fernandez","year":"2004","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/338260","article-title":"Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile","volume":"34","author":"Kyne","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2011.07.005_bib25","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1128\/IAI.55.12.2984-2992.1987","article-title":"Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters","volume":"55","author":"Kim","year":"1987","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib26","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1128\/IAI.59.6.2215-2218.1991","article-title":"Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate","volume":"59","author":"Lyerly","year":"1991","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.idc.2011.07.005_bib27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1086\/657116","article-title":"Management of Clostridium difficile infection: thinking inside and outside the box","volume":"51","author":"Gerding","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM200002103420604","article-title":"Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A","volume":"342","author":"Kyne","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10620-010-1411-2","article-title":"Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review","volume":"56","author":"Abougergi","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijid.2008.11.012","article-title":"The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review","volume":"13","author":"O\u2019Horo","year":"2009","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/gut.41.3.366","article-title":"Intravenous immunoglobulin therapy for severe Clostridium difficile colitis","volume":"41","author":"Salcedo","year":"1997","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"RR-17","key":"10.1016\/j.idc.2011.07.005_bib33","first-page":"1","volume":"55","author":"Kretsinger","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"12","key":"10.1016\/j.idc.2011.07.005_bib34","first-page":"365","article-title":"Tetanus surveillance\u2014United States, 2001\u20132008","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-154-5-201103010-00007","article-title":"Narrative review: tetanus\u2013a health threat after natural disasters in developing countries","volume":"154","author":"Afshar","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.idc.2011.07.005_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602-614.2000","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.idc.2011.07.005_bib37","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.idc.2011.07.005_bib38","unstructured":"Organization WH. WHO vaccine-preventable diseases monitoring system: 2010 global summary, vol.\u00a02. Geneva (Switzerland): World Health Organization; 2010. p. R-234."},{"key":"10.1016\/j.idc.2011.07.005_bib39","series-title":"CDC health information for international travel 2010","author":"Centers for Disease Control and Prevention","year":"2009"},{"issue":"17","key":"10.1016\/j.idc.2011.07.005_bib40","first-page":"380","article-title":"Availability of diphtheria antitoxin through an investigational new drug protocol","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.idc.2011.07.005_bib41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM198710223171703","article-title":"Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients","volume":"317","author":"Snydman","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2011.07.005_bib42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.7326\/0003-4819-119-10-199311150-00004","article-title":"Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial","volume":"119","author":"Snydman","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2011.07.005_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005129.pub2","article-title":"Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Hodson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2011.07.005_bib44","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib45","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/TP.0b013e3181ea3955","article-title":"An international survey of cytomegalovirus management practices in lung transplantation","volume":"90","author":"Zuk","year":"2010","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.idc.2011.07.005_bib46","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.transproceed.2007.06.050","article-title":"The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections","volume":"39","author":"Carbone","year":"2007","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.idc.2011.07.005_bib47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"issue":"16","key":"10.1016\/j.idc.2011.07.005_bib48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJM198604173141602","article-title":"Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation","volume":"314","author":"Bowden","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"3A","key":"10.1016\/j.idc.2011.07.005_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(84)90332-2","article-title":"Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients","volume":"76","author":"Condie","year":"1984","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-106-1-12","article-title":"Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation","volume":"106","author":"Winston","year":"1987","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","article-title":"Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial","volume":"139","author":"Cordonnier","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib53","first-page":"187","article-title":"Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir","volume":"4","author":"Verdonck","year":"1989","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.idc.2011.07.005_bib54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-109-10-783","article-title":"Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants","volume":"109","author":"Reed","year":"1988","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.30.6.554","article-title":"Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"30","author":"Alexander","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.idc.2011.07.005_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-109-10-777","article-title":"Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin","volume":"109","author":"Emanuel","year":"1988","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.idc.2011.07.005_bib57","first-page":"653","article-title":"The etiology of infectious hepatitis","volume":"134","author":"Havens","year":"1947","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM195501202520303","article-title":"Use of gamma globulin for control of infectious hepatitis in an institution for the mentally retarded","volume":"252","author":"Ashley","year":"1955","journal-title":"N\u00a0Engl J Med"},{"issue":"41","key":"10.1016\/j.idc.2011.07.005_bib59","first-page":"1080","article-title":"Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-7","key":"10.1016\/j.idc.2011.07.005_bib60","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.idc.2011.07.005_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004181.pub2","article-title":"Immunoglobulins for preventing hepatitis A","volume":"2","author":"Liu","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1016\/j.idc.2011.07.005_bib62","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa070546","article-title":"Hepatitis A vaccine versus immune globulin for postexposure prophylaxis","volume":"357","author":"Victor","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"RR-16","key":"10.1016\/j.idc.2011.07.005_bib63","first-page":"1","article-title":"A\u00a0comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.1840100312","article-title":"Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls","volume":"10","author":"Mitsui","year":"1989","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0264-410X(85)90007-6","article-title":"Post-exposure active immunoprophylaxis of spouses of acute viral hepatitis B patients","volume":"3","author":"Roumeliotou-Karayannis","year":"1985","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib66","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/infdis\/138.5.625","article-title":"Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial","volume":"138","author":"Grady","year":"1978","journal-title":"J\u00a0Infect Dis"},{"issue":"21","key":"10.1016\/j.idc.2011.07.005_bib67","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM197511202932101","article-title":"Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis","volume":"293","author":"Redeker","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7326\/0003-4819-88-3-285","article-title":"Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study","volume":"88","author":"Seeff","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2011.07.005_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006005.pub2","article-title":"Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation","volume":"7","author":"Katz","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib70","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1440-1746.2009.06151.x","article-title":"Hepatitis B immunoglobulins and\/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review","volume":"25","author":"Chen","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/jcm.8.6.733-735.1978","article-title":"Antibody to varicella-zoster virus after passive immunization against chickenpox","volume":"8","author":"Gershon","year":"1978","journal-title":"J\u00a0Clin Microbiol"},{"issue":"4","key":"10.1016\/j.idc.2011.07.005_bib72","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/inf.1983.15.issue-4.02","article-title":"Zoster immunoglobulin in varicella prophylaxis. A study among high-risk patients","volume":"15","author":"Hanngren","year":"1983","journal-title":"Scand J Infect Dis"},{"issue":"RR-11","key":"10.1016\/j.idc.2011.07.005_bib73","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention","volume":"45","year":"1996","journal-title":"MMWR Recomm Rep"},{"issue":"RR-4","key":"10.1016\/j.idc.2011.07.005_bib74","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"3A","key":"10.1016\/j.idc.2011.07.005_bib75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0002-9343(84)90330-9","article-title":"Varicella zoster antibody titers after the administration of intravenous immune serum globulin or varicella zoster immune globulin","volume":"76","author":"Paryani","year":"1984","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib76","first-page":"773","article-title":"Laboratory data supporting the clinical trial of anti-rabies serum in persons bitten by a rabid wolf","volume":"13","author":"Habel","year":"1955","journal-title":"Bull World Health Organ"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2011.07.005_bib77","first-page":"S766","article-title":"Use of serum and vaccine in combination for\u00a0prophylaxis following exposure to rabies","volume":"10","author":"Lin","year":"1988","journal-title":"Rev Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0264-410X(95)00213-K","article-title":"What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?","volume":"14","author":"Khawplod","year":"1996","journal-title":"Vaccine"},{"issue":"RR-3","key":"10.1016\/j.idc.2011.07.005_bib79","first-page":"1","article-title":"Human rabies prevention\u2013United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.idc.2011.07.005_bib80","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/infdis\/165.6.987","article-title":"An outbreak of respiratory syncytial virus in a bone marrow transplant center","volume":"165","author":"Harrington","year":"1992","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib81","first-page":"393","article-title":"Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients","volume":"16","author":"Whimbey","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.idc.2011.07.005_bib82","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1702228","article-title":"Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin","volume":"25","author":"Ghosh","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2011.07.005_bib83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","article-title":"Adverse effects of intravenous immunoglobulin therapy","volume":"21","author":"Nydegger","year":"1999","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.idc.2011.07.005_bib84","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00006454-199108000-00010","article-title":"Enteral immunoglobulins for treatment of protracted rotaviral diarrhea","volume":"10","author":"Guarino","year":"1991","journal-title":"Pediatr Infect Dis J"},{"issue":"8851","key":"10.1016\/j.idc.2011.07.005_bib85","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0140-6736(93)91136-A","article-title":"Oral immunoglobulin treatment in Campylobacter jejuni enteritis","volume":"341","author":"Hammarstrom","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.idc.2011.07.005_bib86","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/adc.79.1.48","article-title":"Immunoglobulin replacement treatment by rapid subcutaneous infusion","volume":"79","author":"Gaspar","year":"1998","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP1516","article-title":"Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load","volume":"15","author":"Dennert","year":"2010","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.idc.2011.07.005_bib88","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.autrev.2004.10.004","article-title":"Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.idc.2011.07.005_bib89","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/clinids\/9.2.334","article-title":"Chronic enteroviral meningoencephalitis in agammaglobulinemic patients","volume":"9","author":"McKinney","year":"1987","journal-title":"Rev Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552011000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552011000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:39:58Z","timestamp":1639528798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552011000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0891552011000535"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2011.07.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}